Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Chromosome 20 loss is characteristic of breast implant–associated anaplastic large cell lymphoma

G. Tjitske Los-de Vries, Mintsje de Boer, Erik van Dijk, Phylicia Stathi, Nathalie J. Hijmering, Margaretha G. M. Roemer, Matias Mendeville, Daniel M. Miedema, Jan Paul de Boer, Hinne A. Rakhorst, Flora E. van Leeuwen, René R. W. J. van der Hulst, Bauke Ylstra, Daphne de Jong

Blood (2020) 136 (25): 2927–2932.

https://doi.org/10.1182/blood.2020005372

Published: 2020

Includes: Supplemental data

Journal Articles

Increased prevalence of BRCA1/2 mutations in women with macrotextured breast implants and anaplastic large cell lymphoma of the breast

Mintsje de Boer, Michael Hauptmann, Nathalie J. Hijmering, Carel J. M. van Noesel, Hinne A. Rakhorst, Hanne E. J. Meijers-Heijboer, Jan Paul de Boer, René R. W. J. van der Hulst, Daphne de Jong, Flora E. van Leeuwen

Blood (2020) 136 (11): 1368–1372.

https://doi.org/10.1182/blood.2019004498

Published: 2020

Includes: Supplemental data

Journal Articles

Nivolumab Treatment Beyond Investigator-Assessed Progression: Extended Follow-up in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma from the Phase 2 CheckMate 205 Study

Jonathon B. Cohen, MDMS, John Kuruvilla, MD, Andreas Engert, MD, Stephen M. Ansell, MD PhD, Anas Younes, MD, Hun Ju Lee, MD, Marek Trněný, Kerry J Savage, BSc, MD MSc, Radhakrishnan Ramchandren, MD, Graham P. Collins, MB BS DPhil, Pier Luigi Zinzani, MD, Jan Paul De Boer, MD PhD, Margaret A. Shipp, MD, Armando Santoro, MD, John M. Timmerman, MD, Mariana Sacchi, MD, Oumar Sy, PhD, Philippe Armand, MD PhD

Blood (2018) 132 (Supplement 1): 2932.

https://doi.org/10.1182/blood-2018-99-114502

Published: 2018

Journal Articles

Nivolumab for Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) after Autologous Hematopoietic Cell Transplantation (auto-HCT): Extended Follow-up of the Phase 2 Single-Arm CheckMate 205 Study

Philippe Armand, MD PhD, Andreas Engert, MD, Anas Younes, MD, Hun Ju Lee, MD, Armando Santoro, MD, Pier Luigi Zinzani, MD, John M. Timmerman, MD, Graham P. Collins, MB BS DPhil, Radhakrishnan Ramchandren, MD, Jonathon B. Cohen, MD MS, Jan Paul De Boer, MD PhD, Kerry J Savage, BSc, MD MSc, John Kuruvilla, MD, Marek Trněný, Margaret A. Shipp, MD, Mariana Sacchi, MD, Anne Sumbul, MS, Stephen M. Ansell, MD PhD

Blood (2018) 132 (Supplement 1): 2897.

https://doi.org/10.1182/blood-2018-99-112067

Published: 2018

Journal Articles

Nivolumab Treatment Beyond Investigator-Assessed Progression: Outcomes in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma from the Phase 2 Checkmate 205 Study

Jonathon B Cohen, MDMS, Andreas Engert, MD, Stephen M Ansell, MD PhD, Anas Younes, MD, Marek Trneny, MD, Kerry J Savage, BSc, MD MSc, Radhakrishnan Ramchandren, MD, Graham Collins, MD PhD, Michelle A. Fanale, MD, Philippe Armand, MD PhD, Pier Luigi Zinzani, MD PhD, Jan Paul De Boer, MD PhD, Margaret A. Shipp, MD, Armando Santoro, MD, John M Timmerman, MD, Mariana Sacchi, Oumar Sy, PhD, John Kuruvilla, MD

Blood (2017) 130 (Supplement 1): 650.

https://doi.org/10.1182/blood.V130.Suppl_1.650.650

Published: 2017

Journal Articles

Expression of Major Histocompatibility Complex (MHC) Class II, but Not MHC Class I, Predicts Outcome in Patients with Classical Hodgkin Lymphoma (cHL) Treated with Nivolumab (Programmed Death-1 [PD-1] Blockade)

Blood (2017) 130 (Supplement 1): 1450.

https://doi.org/10.1182/blood.V130.Suppl_1.1450.1450

Published: 2017

Journal Articles

Checkmate 205 Update with Minimum 12-Month Follow up: A Phase 2 Study of Nivolumab in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma

John M. Timmerman, MD, Andreas Engert, MD, Anas Younes, MD, Armando Santoro, Philippe Armand, MD PhD, Michelle A Fanale, MD, Graham P. Collins, MD PhD, Voravit Ratanatharathorn, MD, John Kuruvilla, MD, Jonathon B. Cohen, MD, Kerry J Savage, MD, Marek Trneny, Jan Paul De Boer, MD PhD, Margaret A. Shipp, MD, Scott J Rodig, Kazunobu Kato, MD, Anne Sumbul, Stephen Ansell, MD PhD

Blood (2016) 128 (22): 1110.

https://doi.org/10.1182/blood.V128.22.1110.1110

Published: 2016

Journal Articles

Risk of multiple primary malignancies following treatment of Hodgkin lymphoma

Anna M. van Eggermond, Michael Schaapveld, Pieternella J. Lugtenburg, Augustinus D. G. Krol, Jan Paul de Boer, Josée M. Zijlstra, John M. M. Raemaekers, Leontien C. M. Kremer, Judith M. Roesink, Marieke W. J. Louwman, Berthe M. P. Aleman, Flora E. van Leeuwen

Blood (2014) 124 (3): 319–327.

https://doi.org/10.1182/blood-2013-10-532184

Published: 2014

Includes: Supplemental data

Journal Articles

In vivo p53 response and immune reaction underlie highly effective low-dose radiotherapy in follicular lymphoma

Laurent Knoops, Rick Haas, Sanne de Kemp, Donné Majoor, Annegien Broeks, Eric Eldering, Jan Paul de Boer, Marcel Verheij, Conny van Ostrom, Annemieke de Vries, Laura van't Veer, Daphne de Jong

Blood (2007) 110 (4): 1116–1122.

https://doi.org/10.1182/blood-2007-01-067579

Published: 2007

Includes: Supplemental data

Journal Articles

Late cardiotoxicity after treatment for Hodgkin lymphoma

Berthe M. P. Aleman, Alexandra W. van den Belt-Dusebout, Marie L. De Bruin, Mars B. van 't Veer, Margreet H. A. Baaijens, Jan Paul de Boer, Augustinus A. M. Hart, Willem J. Klokman, Marianne A. Kuenen, Gabey M. Ouwens, Harry Bartelink, Flora E. van Leeuwen

Blood (2006) 109 (5): 1878–1886.

https://doi.org/10.1182/blood-2006-07-034405

Published: 2006

Journal Articles

Attacking Oncogene Addiction in B-CLL: Seliciclib First Engages the Mcl-1/Noxa Axis, after Which Gradual Exhaustion of Bcl-2 Protection Leads to Bax Activation.

Delfine Y.H. Hallaert, Rene Spijker, Margot Jak, Annelieke Jaspers, Ingrid A.M. Derks, Nuno L. Alves, Drs, Jan Paul de Boer, Daphne de Jong, MD, Simon R. Green, Rene A.W. van Lier, MD, PhD, Marinus H.J. van Oers, MD, PhD, Eric Eldering, PhD

Blood (2006) 108 (11): 2103.

https://doi.org/10.1182/blood.V108.11.2103.2103

Published: 2006

Journal Articles

The Novel Cancer Drug Seliciclib Engages the Mitochondrial Apoptosis Pathway Via the Mcl-1/Noxa Axis in CLL.

Delfine Hallaert, Rene Spijker, Ingrid A.M. Derks, Margot Jak, MD, Bart de Goeij, Jan Paul de Boer, MD, PhD, Daphne de Jong, MD, PhD, Simon R. Green, Rene van Lier, MD, PhD, Eric Eldering, PhD, Marinus H.J. Van Oers, MD, PhD

Blood (2005) 106 (11): 2983.

https://doi.org/10.1182/blood.V106.11.2983.2983

Published: 2005

NARROW

Chromosome 20 loss is characteristic of breast implant–associated anaplastic large cell lymphoma

Increased prevalence of BRCA1/2 mutations in women with macrotextured breast implants and anaplastic large cell lymphoma of the breast

Nivolumab Treatment Beyond Investigator-Assessed Progression: Extended Follow-up in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma from the Phase 2 CheckMate 205 Study

Nivolumab for Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) after Autologous Hematopoietic Cell Transplantation (auto-HCT): Extended Follow-up of the Phase 2 Single-Arm CheckMate 205 Study

Nivolumab Treatment Beyond Investigator-Assessed Progression: Outcomes in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma from the Phase 2 Checkmate 205 Study

Expression of Major Histocompatibility Complex (MHC) Class II, but Not MHC Class I, Predicts Outcome in Patients with Classical Hodgkin Lymphoma (cHL) Treated with Nivolumab (Programmed Death-1 [PD-1] Blockade)

Checkmate 205 Update with Minimum 12-Month Follow up: A Phase 2 Study of Nivolumab in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma

Risk of multiple primary malignancies following treatment of Hodgkin lymphoma

In vivo p53 response and immune reaction underlie highly effective low-dose radiotherapy in follicular lymphoma

Late cardiotoxicity after treatment for Hodgkin lymphoma

Attacking Oncogene Addiction in B-CLL: Seliciclib First Engages the Mcl-1/Noxa Axis, after Which Gradual Exhaustion of Bcl-2 Protection Leads to Bax Activation.

The Novel Cancer Drug Seliciclib Engages the Mitochondrial Apoptosis Pathway Via the Mcl-1/Noxa Axis in CLL.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only